Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil (INSPIRE) 2018-09-07T13:58:08+00:00

Clinical Trials

July 11, 2018

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil (INSPIRE)

  • Study Sponsor: Liquidia Technologies
  • Institution: Liquidia Technologies
  • Start Date: Tuesday, January 2, 2018
  • End Date: Active but not recruiting
  • Design: 
    •  Open-label
  • Age range (years): 18 to 100
  • Type of PH
    • IPAH
    • Heritable – APAH
    • CTD – APAH
    • CHD – APAH
    • Toxic – APAH
    • HIV – APAH
    • Hem – APAH
  • Study Duration for individual patient: Indefinite duration
  • Contact: https://www.clinicaltrials.gov/ct2/show/NCT03399604